Peptide Vendor COA Grades
August 2026 Results

Peptide Protocols has completed a new comparative review of testing evidence published by 39 peptide vendors. Release version v2.5 applies the same finalized review framework and the same August 30 evidence-audit date to every displayed score.

The release produced four A grades, 27 B grades and eight C grades. Scores range from 72 to 92, with a median of 84 and an average of 83.6. No vendor in the graded cohort received a D or F.

The grades measure the strength, breadth and traceability of each vendor's available testing program. They do not measure customer service, shipping speed, price, community popularity or medical suitability—and they do not certify that every vial matches a published report.

The largest group is the B band: 27 of 39 vendors scored between 80 and 89. Eight vendors scored in the C band between 70 and 79, while four reached the A band at 90 or above.

The concentration in the B range is informative. Many vendors now publish current third-party testing across meaningful portions of their catalogs. The remaining separation comes from the overall strength, relevance and verifiability of the evidence—not from a single favorable purity result.

Four testing programs reached the A band in the August 2026 release:

The lower overall grades are not primarily the result of vendors suddenly publishing fewer COAs. A major factor is a change in how much confidence Peptide Protocols currently places in evidence issued by ILS Labs.

Negative information and unresolved reliability questions involving ILS became relevant during the review period. As a result, ILS was moved into a provisional lower-confidence laboratory tier while we wait for stronger evidence of reliability and resolution. Because ILS reports appear throughout a substantial number of vendor testing libraries, that reassessment affected multiple vendor grades at the same time.

This is an evidence-confidence adjustment, not a declaration that every ILS report is false, that every result is inaccurate or that every product supported by an ILS report failed testing. It means those reports currently carry less weight in our comparative review than evidence from laboratories with stronger independent validation and fewer unresolved concerns.

One of the most striking findings in the v2.5 review was how often ILS appeared across otherwise unrelated peptide vendors. ILS reports were present in the current scored evidence of 17 of 39 vendors, or 43.6%, and ILS was the dominant or plurality laboratory for approximately 11 vendors.

ILS did not have the broadest vendor reach; Freedom Diagnostics appeared across 21 vendors. ILS nevertheless handled conspicuously high report volumes in several of the market's largest testing libraries. Two reviewed vendor libraries each contained more than 120 current ILS reports, while several others contained roughly 40 to 70. That volume helps explain why a change in confidence toward ILS moved overall grades so visibly.

That concentration creates a market-wide evidence risk. Dozens of vendor pages can appear to represent independent testing programs while depending on a much smaller laboratory ecosystem behind the scenes. When confidence in one frequently used laboratory changes, the effect is not isolated to one vendor—it can move a large portion of the directory at once.

The pattern also reinforces why Peptide Protocols evaluates the laboratory behind a report rather than awarding equal confidence to every document labeled “third-party tested.” A vendor can be organizationally separate from a laboratory while still relying heavily on the same analytical source used throughout the market.

We are intentionally not publishing vendor-by-vendor scoring mechanics, laboratory weights or the numerical effect of this reassessment. The public point is narrower: laboratory concentration matters, and v2.5 reflects the current confidence level of the evidence source rather than treating all third-party reports as equivalent.

The reputation change was not based on one unfavorable analytical result. It followed a growing collection of publicly circulated certificates, cross-laboratory discrepancies and customer or vendor complaints involving sample handling, report provenance, unexpected testing, turnaround times and communication.

These issues do not establish that ILS fabricated results, that every complaint is accurate or that every ILS certificate is unreliable. They do explain why v2.5 assigns provisional lower confidence to ILS-backed evidence until report quality, operational reliability, method transparency and independent validation improve.

The v2.5 framework reviews the overall strength of the testing evidence a vendor makes available. It considers whether that evidence is relevant, current, traceable, independently credible and sufficiently consistent to support comparison across vendors.

Peptide Protocols publishes the principles behind the grade and the limits of what it can prove. Exact weights, thresholds, internal decision rules and calibration mechanics remain proprietary. That boundary prevents the framework from becoming a checklist vendors or competitors can optimize without materially improving the underlying testing program.

A report from one vial can provide meaningful evidence about that submitted sample. It cannot establish how consistent the rest of the batch is. The review therefore considers the strength of any documented sampling beyond a single submitted vial.

Where sampling information is disclosed, the review distinguishes meaningful independent samples from pooled material or repeated measurements of the same sample. The exact scoring thresholds and component effects are not published.

Sampling depth is only one part of the overall evidence review. It cannot compensate for weak traceability, unclear laboratory attribution or incomplete analytical evidence.

A professional-looking PDF is not enough. The review distinguishes the analytical laboratory from marketplaces, referral platforms and vendor-controlled testing layers. Credit reflects the identified bench laboratory and the strength of the available verification trail.

Laboratory credibility is also separate from the reported result. A report may show favorable purity and identity findings while still earning less confidence if the issuing laboratory has limited validation, cannot be clearly identified or lacks a reliable independent verification pathway.

The score therefore asks two questions at once: what did the report say, and how much confidence can be placed in the chain connecting that result to an identifiable independent laboratory?

Use the grade as a comparative starting point, then open the vendor profile and inspect the underlying testing pattern. The score is most useful for identifying where a testing program appears broad, current and traceable—and where meaningful gaps remain.

For a specific product, verify that the report matches the compound, strength and lot being sold. Check identity, chromatographic purity and quantitative peptide content as separate results. If sterility, endotoxin, heavy metals or residual solvents matter to the question being asked, confirm that those panels are actually present rather than inferred from a headline purity percentage.

The vendor directory displays the current scores. Our guide to reading a peptide COA explains how to inspect individual reports, while the COA grading methodology explains what the site-wide grade does and does not measure.

Even the highest grade cannot prove that an untested vial contains the claimed compound, that every vial in a batch is identical, or that the customer will receive the same batch represented by a published report.

The grades do not establish sterility or injectable safety when the relevant tests are missing. They do not account for storage, handling or transit after sampling. They are not pharmacy credentials, regulator findings, medical recommendations or endorsements of human use.

Testing programs also change. Vendors may publish new reports, switch laboratories, expand sampling or remove evidence. Each score should be read with its audit date, and material new evidence may change a future grade.

Multiple vendors have told Peptide Protocols that they are moving new testing away from ILS Labs following recent events. Several also said their newest batches and replacement laboratory reports will not be fully represented in their online stores until the early weeks of September.

Those statements describe vendor-reported plans, not completed evidence. Grades will change only after the relevant reports are publicly available or otherwise submitted, reviewed and verified under the same framework.

To account for the transition, Peptide Protocols will temporarily move from a monthly COA grading routine to approximately two releases per month, targeting a mid-month review and a second review near month-end. This gives new batches and replacement reports a reasonable opportunity to appear without forcing readers to wait an entire month for the next comparison.

The twice-monthly schedule is temporary. We may return to monthly releases once laboratory transitions stabilize and the volume of material becomes more predictable. Reviewing catalogs, matching batches, checking reports and laboratories, resolving discrepancies, recalculating grades and validating the site-wide release is a substantial manual workload. Publication frequency must remain compatible with a defensible review.

The August 2026 results show that public peptide-vendor testing is becoming broader and more structured. Most vendors in the graded cohort now fall in the B range, and four testing programs met the A-grade threshold.

The remaining differences are not captured by marketing phrases such as “third-party tested.” They depend on whether reports cover the catalog, match current batches, come from credible laboratories, include the right analytical panels and provide enough same-batch sampling to say more than one submitted vial happened to test well.

The release makes those differences easier to compare. It does not remove the need to read the reports themselves.